Zelos Therapeutics, Inc.

October 18, 2005 08:38 ET

Zelos Therapeutics Appoints Brian MacDonald as Chief Executive Officer

WALTHAM, Mass. and OTTAWA, Ontario--(CCNMatthews - Oct 18, 2005) -

Zelos Therapeutics, Inc. announced today the appointment of Brian MacDonald, MB, ChB, PhD as Chief Executive Officer. Dr. MacDonald brings a strong track record of achievement in the pharmaceutical industry to Zelos, with a particular emphasis on the development of novel therapeutics for the treatment of osteoporosis.

"Brian's industry experience, particularly in managing the development and strategic objectives of bringing a new drug into the osteoporosis market, makes him an excellent fit to lead Zelos," said Farah Champsi, Chairperson of the Company's Board of Directors. "We have been fortunate to have benefited from Brian's experience over the past year while he served as a consultant to Zelos and we are confident that he has the skills to help the company achieve its clinical, operational and business development goals."

"Over the past year, I have had the privilege of getting to know the Zelos team as well as gaining working knowledge of the Company's business and core operational strategy," said Dr. MacDonald. "Zelos represents a very exciting opportunity because of the quality of the management team, its scientific excellence and the promise of Ostabolin-C as an important new treatment for osteoporosis. I am honored to take on the position of CEO and look forward to leading Zelos as it enters this new phase in its development."

Brian MacDonald joined SmithKline Beecham Clinical R&D in 1995 and assumed worldwide responsibility for osteoporosis and rheumatology, a role that he extended following the merger to form GlaxoSmithKline to include a range of therapeutic areas including dermatology and analgesia. In 2002 he joined 3-Dimensional Pharmaceuticals as Head of Development, until the acquisition of that organization by J&J in 2003. Since then he has consulted on R&D strategy for numerous early stage biotech companies, most recently as Head of Clinical and Regulatory Affairs for Gentara Corporation.

Dr. MacDonald received his PhD and MB, ChB from the University of Sheffield in the UK after which he undertook specialty clinical training in metabolic bone disease and rheumatology.

As part of Dr. MacDonald's appointment as CEO, Zelos will relocate its U.S. headquarters from Waltham, Massachusetts to Philadelphia, Pennsylvania.

About Zelos

Zelos Therapeutics, Inc. is a private biopharmaceutical company that is developing breakthrough discoveries in Parathyroid Hormone (PTH) research. Product programs include the development of a next-generation PTH analogue, Ostabolin-C™, for the treatment of osteoporosis that is currently in Phase II trials and a PTH agonist for the topical treatment of psoriasis, also in clinical development. The Company has a collaboration with Nektar Therapeutics for the development of a pulmonary formulation of Ostabolin-C™ for the treatment of osteoporosis. Zelos maintains administrative offices in Waltham, Mass. and research facilities in Ottawa, Ontario. More information is available at www.zelostherapeutics.com.

Contact Information

  • For Zelos Therapeutics, Inc.:
    Farah Champsi, 415-362-4022
    Chairperson of the Board of Directors
    Alta Partners
    or
    Godfrey Marchand, 613-747-1491
    Vice President, Corporate Affairs
    Zelos Therapeutics
    or
    Media Contact:
    Kari Watson, 508-647-0209
    MacDougall Biomedical Communications
    kwatson@macbiocom.com